Literature DB >> 26418699

Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.

Michiel Haeseker1, Sander Croes, Cees Neef, Cathrien Bruggeman, Leo Stolk, Annelies Verbon.   

Abstract

BACKGROUND: The aim of this study was to investigate whether vancomycin clearance (CLva) can be adequately predicted with CLva prediction methods. Additionally, other covariates influencing the CLva were investigated and predictivity of monitoring of only trough levels to 24-hour area under the curve (AUC24) was evaluated.
METHODS: Routine vancomycin plasma levels were measured with a fluorescence polarization immunoassay. Pharmacokinetic (PK) parameters of individual patients, that is, CLva and volume of distribution, were determined with maximum a posteriori Bayesian estimation. CLva was calculated with the 3 prediction methods, which are solely based on creatinine clearance (CLcr) estimated with Cockcroft and Gault formula and was compared with the calculated CLva with maximum a posteriori Bayesian estimation. Prediction errors were calculated. Correlations between CLva and CLcr, creatinine, age, weight, sex, and neutropenia were made. Furthermore, correlations between trough levels and AUC24 were evaluated.
RESULTS: A total of 171 patients were included. Prediction errors and absolute prediction errors of the 3 methods ranged from 28% to 80% and 39% to 83%, respectively. In the multivariate analysis, CLva was significantly associated with CLcr, creatinine, age, weight, sex, and neutropenia. Linear correlation between AUC24 and trough levels was R(2) 0.38.
CONCLUSIONS: Large prediction errors make the CLva algorithms based on estimated plasma CLcr unsuitable for use in patient care. Additionally, other factors, which are not accounted for in the current algorithms, influence the CLva individually. Owing to low association of AUC24 and trough levels, the AUC24 cannot be predicted with through levels. For a reliable AUC24 guided vancomycin dosing, therapeutic drug monitoring is necessary.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26418699     DOI: 10.1097/FTD.0000000000000250

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

Review 1.  Review of vancomycin-induced renal toxicity: an update.

Authors:  Oluwatoyin Bamgbola
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-30       Impact factor: 3.565

Review 2.  A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.

Authors:  Na He; Fei Dong; Wei Liu; Suodi Zhai
Journal:  Infect Drug Resist       Date:  2020-06-16       Impact factor: 4.003

3.  Area under the Curve-Based Dosing of Vancomycin in Critically Ill Patients Using 6-Hour Urine Creatinine Clearance Measurement.

Authors:  Bita Shahrami; Farhad Najmeddin; Saeideh Ghaffari; Atabak Najafi; Mohammad Reza Rouini; Mojtaba Mojtahedzadeh
Journal:  Crit Care Res Pract       Date:  2020-12-24

Review 4.  Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review.

Authors:  Anri Sawada; Kunio Kawanishi; Shohei Morikawa; Toshihiro Nakano; Mio Kodama; Mitihiro Mitobe; Sekiko Taneda; Junki Koike; Mamiko Ohara; Yoji Nagashima; Kosaku Nitta; Takahiro Mochizuki
Journal:  BMC Nephrol       Date:  2018-03-27       Impact factor: 2.388

5.  Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: A Multicenter Retrospective Study.

Authors:  Yanli Hou; Jiajia Ren; Jiamei Li; Xuting Jin; Ya Gao; Ruohan Li; Jingjing Zhang; Xiaochuang Wang; Xinyu Li; Gang Wang
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

6.  An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: A multicenter retrospective study.

Authors:  Jiajia Ren; Yanli Hou; Jiamei Li; Ya Gao; Ruohan Li; Xuting Jin; Jingjing Zhang; Xiaochuang Wang; Gang Wang
Journal:  Clin Transl Sci       Date:  2021-04-09       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.